Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Reliable Diagnostic Test Developed for Scabies

By LabMedica International staff writers
Posted on 22 Nov 2011
A fluoroimmunoassay has been developed to determine the specific antibodies in the blood of patients infested with the human itch mite, Sarcoptes scabiei. More...


Scabies antigen specific immunoglobulin E (IgE) was measured by a dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) and quantified, while a competitive inhibition enzyme-linked immunosorbent assay (ELISA) was also conducted.

Scientists from the Menzies School of Health Research, (Darwin, NT, Australia) collaborated with other institutions, to create recombinant allergens to S. scabiei and house dust mites (HDM). Specific IgE antibodies to a major scabies antigen recombinant Sar s 14.3 (rSar s 14.3) were measured in 140 plasma samples from scabies-infested and control subject groups. The 140 consenting volunteers consisted of six groups: 30 subjects with crusted scabies; 30 subjects with ordinary scabies; 30 previously exposed but currently noninfested subjects; 30 subjects naïve to scabies; 10 naïve subjects with atopic allergy as defined by positive skin prick test to a panel of common aeroallergens; and 10 naïve subjects with known allergy to human dust mites based on clinical history and positive specific IgE.

The mean IgE binding to the recombinant antigen for the crusted scabies group was significantly greater compared to each of the other groups. The ordinary scabies group also had a significantly higher mean value than each noninfested group, and the exposed but noninfested group's mean IgE response was significantly greater than the mean response for the naïve to scabies group. The recombinant antigen DELFIA (Wallac; Turku, Finland) showed excellent diagnostic capability, with 100% sensitivity and 93.75% specificity for distinguishing subjects with current scabies infestation from control, uninfested subjects.

The authors concluded that the results demonstrate sensitive detection of IgE reactivity with genus-specific scabies mite epitopes and differential diagnosis of scabies mite allergy from allergy to HDM. The recombinant antigen specific IgE DELFIA has high diagnostic efficiency, with accuracy superior to other diagnostic methods currently available for scabies. Due to the high sensitivity, specificity, accuracy, predictive values, and area under the ROC curve, the developed DELFIA represents a marked improvement for the clinical diagnosis of scabies and helps direct future development of a specific diagnostic tool for scabies. The study was published on October 21, 2011, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Menzies School of Health Research
Wallac


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.